Safety and efficacy of caplacizumab retreatment in a real-life monocentric cohort of patients with immune-mediated thrombotic thrombocytopenic purpura.

Caocci, G; Mulas, O; Mantovani, D; Bandinu, N; La Nasa, G

Caocci, G; Mulas, O; Mantovani, D; Bandinu, N; La Nasa, G.

Afiliación

Caocci G; Hematology Unit, Businco Hospital, Department of Medical Sciences and Public Health, University of Cagliari, Italy. Electronic address: giovanni.caocci@unica.it.
Mulas O; Hematology Unit, Businco Hospital, Department of Medical Sciences and Public Health, University of Cagliari, Italy.
Mantovani D; Hematology Unit, Businco Hospital, Department of Medical Sciences and Public Health, University of Cagliari, Italy.
Bandinu N; Hematology Unit, Businco Hospital, Department of Medical Sciences and Public Health, University of Cagliari, Italy.
La Nasa G; Hematology Unit, Businco Hospital, Department of Medical Sciences and Public Health, University of Cagliari, Italy.

Thromb Res ; 228: 189-190, 2023 08.

Article en En | MEDLINE | ID: mdl-37348319

Asunto(s)

Púrpura Trombocitopénica Trombótica; Anticuerpos de Dominio Único; Humanos; Púrpura Trombocitopénica Trombótica/tratamiento farmacológico; Factor de von Willebrand; Intercambio Plasmático; Proteína ADAMTS13

Palabras clave

Caplacizumab; TTP retreatment; Thrombotic thrombocytopenic purpura

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Púrpura Trombocitopénica Trombótica / Anticuerpos de Dominio Único Límite: Humans Idioma: En Revista: Thromb Res Año: 2023 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google